SCHEMBL29631815

SCHEMBL29631815

Cc1cccc2c1cc(Cn1c(=O)c3c(nc(Br)n3C)n(C)c1=O)n2C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ LMNA P02545 7/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ SMN1; SMN2 Q16637 5/20 0.38
▸ TSHR P16473 5/20 0.38
▸ POLB P06746 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ PRNP P04156 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18990310 1.00 TNF (0.42) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL19013546 0.92 ALDH1A1 (0.44) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL29631881 0.92 ALDH1A1 (0.44) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL18989624 0.91 ALDH1A1 (0.45) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL29631846 0.91 ALDH1A1 (0.45) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL29631801 0.91 ALDH1A1 (0.41) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL18990243 0.91 ALDH1A1 (0.41) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL29631807 0.90 ALDH1A1 (0.41) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL18989570 0.89 TNF (0.44) TNFALDH1A1HPGDHIF1ALMNA
SCHEMBL29632018 0.89 TNF (0.44) TNFALDH1A1HPGDHIF1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2022-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 TNF 3037/4885ALDH1A1 260/4885HPGD 188/4885
US-11370792-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 TNF 3037/4885ALDH1A1 260/4885HPGD 188/4885
US-20230067237-A1 CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF MTHFD2, MTHFD1, NUDT15 TNF 3037/4885ALDH1A1 260/4885HPGD 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback